CoChat

Daratumumab in multiple myeloma

Open access
Nooka, Ajay K., Kaufman, Jonathan L., Hofmeister, Craig C., Joseph, Nisha S., Heffner, Thomas L., Gupta, Vikas A., Sullivan, Harold C., Neish, Andrew S., Dhodapkar, Madhav V., Lonial, Sagar · 2019 · Cancer
Cited by 162

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Abstract

The development of effective monoclonal antibodies for the treatment of myeloma has been a long journey of clinical and drug development. Identification of the right target antigen was a critical part of the process. CD38 as a target has been considered for some time, but clinically, daratumumab, a CD38 monoclonal antibody, was the first to be tested, and it has delivered the best clinical responses as a single agent to date. Its proven safety and efficacy in combination with other antimyeloma agents have led to several US Food and Drug Administration approvals for treating myeloma. Furthermore, the results of early trials in the induction therapy setting have demonstrated a beneficial role when it is added to the existing induction regimens. This review summarizes the importance of CD38 as a target and examines the clinical development of the CD38 monoclonal antibody daratumumab and its clinical significance in combination regimens in both patients with relapsed/refractory myeloma and patients with newly diagnosed myeloma.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/cncr.32065

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

  • Cancer Statistics, 2017.

    Siegel, R. L., Miller, K. D., & Jemal, A. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21387 · Cited by 14,712

  • Functions of natural killer cells

    Vivier, E., Tomasello, E., Baratin, M., Walzer, T., & Ugolini, S. (2008) · Nature Immunology · doi:10.1038/ni1582 · Cited by 3,943 · cited 1×

    “NK cells are effector lymphocytes that play a key role in the functioning of innate immunity and provide protection against malignancies and other pathogens.(36) NK cell depletion or defects in NK cell activity increased susceptibility to viral infections in mice,(37) and NK cell depletion can potentially have deleter…”
    Background
  • Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.

    Dimopoulos, M. A., Oriol, A., Nahi, H., San-Miguel, J., Bahlis, N. J., Usmani, S. Z., Rabin, N., Orlowski, R. Z., Komarnicki, M., Suzuki, K., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607751 · Cited by 1,445 · cited 1×

    “Patients with a potentially higher risk of respiratory complications received post-infusion medications, which consisted of diphenhydramine on the first and second days after all infusions, a short-acting β2-adrenergic receptor agonist, and a long-acting bronchodilator such as tiotropium or salmeterol.(15) Given the h…”
    Background
  • Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma

    Stewart, A. K., Rajkumar, S. V., Dimopoulos, M. A., Masszi, T., Špička, I., Oriol, A., Hájek, R., Rosiñol, L., Siegel, D. S., Mihaylov, G. G., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411321 · Cited by 1,332 · cited 1×

    “5 months (similar to the findings for the other control arms in this setting).(26,27) The 30-month PFS rates were 58% and”
    Result
  • Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma

    Lonial, S., Dimopoulos, M., Palumbo, A., White, D., Grosicki, S., Spicka, I., Walter-Croneck, A., Moreau, P., Mateos, M.-V., Magen, H., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1505654 · Cited by 1,322 · cited 1×

    “5 months (similar to the findings for the other control arms in this setting).(26,27) The 30-month PFS rates were 58% and”
    ResultSelf-citation
  • Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

    Lokhorst, H. M., Plesner, T., Laubach, J. P., Nahi, H., Gimsing, P., Hansson, M., Minnema, M. C., Lassen, U., Krejcik, J., Palumbo, A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1506348 · Cited by 1,117 · cited 5×

    “On the basis of the findings in this study, an effective dose of daratumumab was determined to be 16 mg/kg.(11) The preliminary efficacy of daratumumab was further confirmed in the open-label, multicenter, phase 2 trial SIRIUS, which included patients who were treated with 3 or more prior lines of therapy (including a…”
    BackgroundMethodInfluential
  • Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial

    Lonial, S., Weiss, B. M., Usmani, S. Z., Singhal, S., Chari, A., Bahlis, N. J., Belch, A., Krishnan, A., Vescio, R. A., Mateos, M. V., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01120-4 · Cited by 854 · cited 3×

    “The preliminary efficacy of daratumumab was further confirmed in the open-label, multicenter, phase 2 trial SIRIUS, which included patients who were treated with 3 or more prior lines of therapy (including a PI and an IMiD) or were double-refractory (refractory to both PI and IMiDs).(12) In part 1 of the study, patien…”
    MethodSelf-citation
  • Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma

    Overdijk, M. B., Verploegen, S., Bögels, M., van Egmond, M., van Bueren, J. J. L., Mutis, T., Groen, R. W., Breij, E., Martens, A. C., Bleeker, W. K., et al. (2015) · mAbs · doi:10.1080/19420862.2015.1007813 · Cited by 521 · cited 2×

    “Macrophages efficiently engulfed daratumumab-coated tumor cells, and this suggests that ADCP is an effective antitumor mechanism of daratumumab.(7) In addition to these immune-mediated mechanisms, daratumumab may also have an immunomodulatory role by depleting CD38+ immune regulatory cells and promoting T-cell expansi…”
    Background
  • Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study

    Kumar, S. K., Dimopoulos, M. A., Kastritis, E., Terpos, E., Nahi, H., Goldschmidt, H., Hillengass, J., Leleu, X., Beksac, M., Alsina, M., et al. (2017) · Leukemia · doi:10.1038/leu.2017.138 · Cited by 351 · cited 1×

    “On the basis of the encouraging activity among double-refractory patients, with a known median overall survival (OS) of 13 months, the use of monoclonal antibodies was rapidly moved to earlier lines of therapy.(2) The results were deeper and more sustained responses with good tolerability.”
    Background
  • Resolving the daratumumab interference with blood compatibility testing

    Chapuy, C. I., Nicholson, R. T., Aguad, M. D., Chapuy, B., Laubach, J. P., Richardson, P. G., Doshi, P., & Kaufman, R. M. (2015) · Transfusion · doi:10.1111/trf.13069 · Cited by 239

Show all 12 references

Cited by

See all 162

Metadata

Authors
Nooka, A. K., Kaufman, J. L., Hofmeister, C. C., Joseph, N. S., Heffner, T. L., Gupta, V. A., Sullivan, H. C., Neish, A. S., Dhodapkar, M. V., & Lonial, S.
Venue
Cancer
Publisher
Wiley
Published
2019-04-05
Volume
125
Issue
14
Pages
2364-2382
ISSN
  • 0008-543X (ISSN-L)
  • 1097-0142
OpenAlex
W2929340554
Cited by
162
References
12
FWCI
11.48
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Daratumumab in multiple myeloma. https://app.cochat.ai/papers/10.1002/cncr.32065
The paper
Nooka, A. K., Kaufman, J. L., Hofmeister, C. C., Joseph, N. S., Heffner, T. L., Gupta, V. A., Sullivan, H. C., Neish, A. S., Dhodapkar, M. V., & Lonial, S. (2019). Daratumumab in multiple myeloma. Cancer. https://doi.org/10.1002/cncr.32065

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.